Amanat Acquisition is a blank check company, or special purpose acquisition company (SPAC), incorporated in the Cayman Islands. The company maintains no operations or revenues and exists solely to raise capital through an initial public offering to acquire or merge with one or more private businesses. Amanat focuses its search on the biotechnology and life sciences sectors, specifically targeting companies with preclinical or clinical-stage data for drugs addressing serious diseases. The company provides private biotech firms with an alternative to traditional initial public offerings by offering public market access and industry expertise. The business model relies on the experience of its management team, which includes individuals with backgrounds in biotechnology leadership and healthcare investment. Amanat has a two-year window from its initial public offering to complete a business combination. If the company fails to complete a deal within this period, it must return the funds held in trust to its shareholders. Notably, Amanat does not issue warrants to its investors, a structure intended to reduce post-combination dilution. The sponsor, Amanat Sponsor Holdings, holds founder shares that convert to ordinary shares upon the completion of a deal, providing a structural incentive to finalize a transaction. The company intends to identify targets that would benefit from public funding to support clinical development or commercialization.